Taficita Tablet
Taficita Tablet is a trusted medication containing Active Pharmaceutical Ingredient, designed for personal use under the guidance of a healthcare professional. Available for prescription-based international supply with discreet worldwide delivery.
- Active ingredient: Emtricitabine
- Form: Tablet
- Indication: HIV-1 infection, Hepatitis B
- Manufacturer: Taficita
This medicine is available to order. Contact us for current pricing and availability.
Request pricing for Taficita Tablet
Our support team will review your request and contact you within 24 hours with pricing and next steps.
Request sent!
What is Emtricitabine?
How Does It Work?
Emtricitabine enters HIV-infected cells and is phosphorylated intracellularly to its active triphosphate form (FTC-TP), which then competes with the natural substrate.
FTC-TP competes with deoxycytidine triphosphate (dCTP) for incorporation into the growing viral DNA chain, causing premature termination of reverse transcription.
Without a functional reverse transcriptase enzyme, HIV cannot complete replication, and consistent dosing maintains undetectable viral loads in most patients.
How to Use
Side Effects & Precautions
- Headache
- Nausea
- Diarrhoea
- Fatigue
- Rash
- Hyperpigmentation of palms and soles
- Lactic acidosis
- Severe hepatomegaly with steatosis
- Immune reconstitution syndrome
- Severe skin reactions
- Severe hypersensitivity to emtricitabine
- Combination with lamivudine (similar mechanism, no additive benefit)
Generic vs Brand
Storage & Handling
Why Buy From Us
Sourced directly from WHO-GMP certified manufacturers.
Every batch tested for purity and bioequivalence.
Discreet shipping to UK, US, AU, EU and beyond.
Regulated and compliant with international pharmacy standards.
Frequently Asked Questions
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with nucleoside analogues.
Severe acute exacerbations of Hepatitis B have been reported in patients co-infected with HIV and HBV upon discontinuation.
Drug Interactions
| Drug / Substance | Effect | Action |
|---|---|---|
| Drugs competing for renal secretion (e.g. ribavirin) | May increase emtricitabine exposure | Monitor for toxicity |
| Lamivudine | Similar mechanism — no additive benefit, added toxicity | Do not use concurrently |
Approved Indications
- HIV-1 infection (combination ART) FDA / EMA
- Hepatitis B virus infection FDA